UPDATE 4-Alnylam's RNAi drug succeeds in key study, shares soar
September 20, 2017 at 15:29 PM EDT
* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.